Lavipharm close to next generation Lavipharm supported once again the Association of Youth Entrepreneurship which the last 8 years cooperates with the country's schools as an educational tool to today's students and future professionals. Through the course of Career Forum, Lavipharm's executives played for a while...
In anticipation of the decrease in drug prices, as expected since the beginning of the year, sales have dropped drastically, due to warehouses and pharmacies' effort to reduce inventories. As a consequence, Lavipharm's Consolidated Turnover fell to Euro 54.1 million from Euro 59.7 million in Q1...
At the opening of the Meeting, Lavipharm's Chairman & CEO, Dr. Athanase Lavidas, referring to the adverse economic situation, both at national and international level, highlighted: "Within this changing environment, and just before completing our first 100 years of operation, we, at Lavipharm, we promptly...
Although, according to IMS data, sales of medicines from pharmacies to consumers dropped only by 0.4%, the turnover of pharmaceutical companies reported a substantial decline, due to the effort of both wholesalers and pharmacies to exhaust reserves (stock out). In particular, the weighted average decline...
In the context of the ASE regulations and under the 3/347/12.07.05 Board Resolution of Hellenic Capital Market Commission, Lavipharm advises that Mr. Ioannis Alexiades assumes the responsibility of Internal Auditor replacing Mr. Georgios Gemelos. ...
New cooperation between Lavipharm & Pfizer. Pfizer Hellas markets Lavipharm's Dolfen in Greece The product will be promoted by Pfizer's sales force and will be marketed under Lavipharm's trademark Dolfen. Lavipharm already markets the product in Greece since 2007 under the brand name Fentadur. Both Fentadur and...
The anticipation of price changes announced by the government at the beginning of the year and implemented consecutively in June and September, led to a decrease in inventory levels throughout the supply chain and consequently to a significant drop in sales, influencing the gross margins...
Consolidated Turnover was formulated at Euro 122,8 million opposed to Euro 119,7 million during the H1 of 2008. The significant retention of operating expenses (-14,0%) improved operating results of the Group, which concluded to profits of Euro 2,6 million opposed to losses of Euro 1,3...
Lavipharm SA, according to the obligations deriving from 3/347/12.07.2005 of the Capital Market Committee, announces that Mrs. Ioanna Tsireka assumes the responsibility of Human Resources Director at Lavipharm Group replacing Mrs. Helen Markou. Mrs. Markou will continue to contribute to Lavipharm as Management Advisor in...
Profitability and constant growth highlight Lavipharm Group financial results of 9M 2009, maintaining its positive course since the beginning of the year. Consolidated Turnover reached Euro 182,9 million compared to Euro 176,4 million during the 9M of 2008. The significant decrease in operating expenses (-14,9%)...
